GraniteShares Advisors LLC Has $713,000 Stake in Edwards Lifesciences Co. (NYSE:EW)

GraniteShares Advisors LLC decreased its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 5.0% in the 1st quarter, HoldingsChannel.com reports. The firm owned 9,839 shares of the medical research company’s stock after selling 515 shares during the period. GraniteShares Advisors LLC’s holdings in Edwards Lifesciences were worth $713,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in EW. Compagnie Lombard Odier SCmA bought a new position in shares of Edwards Lifesciences in the first quarter valued at about $87,000. Spectrum Asset Management Inc. NB CA raised its position in shares of Edwards Lifesciences by 8.2% in the first quarter. Spectrum Asset Management Inc. NB CA now owns 38,543 shares of the medical research company’s stock valued at $2,794,000 after purchasing an additional 2,910 shares during the period. Trueblood Wealth Management LLC raised its position in shares of Edwards Lifesciences by 34.0% in the first quarter. Trueblood Wealth Management LLC now owns 4,949 shares of the medical research company’s stock valued at $359,000 after purchasing an additional 1,256 shares during the period. Terra Alpha Investments LLC raised its position in shares of Edwards Lifesciences by 4.7% in the first quarter. Terra Alpha Investments LLC now owns 22,600 shares of the medical research company’s stock valued at $1,638,000 after purchasing an additional 1,020 shares during the period. Finally, Manitou Investment Management Ltd. increased its position in Edwards Lifesciences by 5.7% during the first quarter. Manitou Investment Management Ltd. now owns 189,656 shares of the medical research company’s stock worth $13,746,000 after acquiring an additional 10,205 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 0.5%

Shares of NYSE EW opened at $75.86 on Friday. The company has a 50 day simple moving average of $74.38 and a 200 day simple moving average of $72.89. The firm has a market cap of $44.50 billion, a PE ratio of 10.88, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $95.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.60 by $0.04. The business had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the business earned $0.66 EPS. On average, research analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 2,570 shares of the firm’s stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $77.40, for a total transaction of $198,918.00. Following the completion of the transaction, the vice president now owns 50,356 shares in the company, valued at approximately $3,897,554.40. This trade represents a 4.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bernard J. Zovighian sold 5,980 shares of the firm’s stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $74.91, for a total transaction of $447,961.80. Following the transaction, the chief executive officer now owns 58,284 shares of the company’s stock, valued at approximately $4,366,054.44. The trade was a 9.31% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 42,948 shares of company stock worth $3,122,845 in the last quarter. 1.29% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts recently commented on EW shares. Truist Financial lowered their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating on the stock in a research report on Friday, April 11th. Wall Street Zen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Friday, May 16th. Citigroup reiterated a “buy” rating and set a $95.00 price objective (up from $84.00) on shares of Edwards Lifesciences in a research note on Thursday, May 22nd. Dbs Bank upgraded shares of Edwards Lifesciences to a “hold” rating in a research note on Monday, June 2nd. Finally, Barclays increased their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $80.20.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.